New Frontiers in the Treatment and Management of Heart Failure: A Closer Look at the Role of Emerging Therapies is a two-part webinar series

New Frontiers in the Treatment and Management of Heart Failure: A Closer Look at the Role of Emerging Therapies is a two-part webinar series is organized by National Association of Managed Care Physicians (NAMCP) and will be held from Jun 01, 2021 - Jun 01, 2023.,,Description:,Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. Fortunately for patients with HF, new and emerging therapeutic options have improved both clinical and economic outcomes for these patients and the system.,,New Frontiers in the Treatment and Management of Heart Failure: A Closer Look at the Role of New Therapies:,• Examine the unmet clinical needs in heart failure and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity,• Review the latest clinical evidence regarding the safety and efficacy of sGC modulators for treating patients with HF with reduced ejection fraction (HFrEF),• Assess the role of sGC modulators and how they fit into current treatment paradigms for the management of HF,• Summarize evidence of HF interventions shown to reduce hospitalizations, morbidity, and mortality,,Recent Advances in the Treatment and Management of Heart Failure: Managed Care Considerations on New and Emerging Therapies:,• Characterize the disease burden of HF in the managed care setting as determined by hospitalizations and other components of morbidity and mortality,• Analyze what managed care and payers need to know about newer therapies in heart failure management,• Examine the latest clinical evidence regarding the safety and efficacy of sGC modulators for treating patients with HF with reduced ejection fraction (HFrEF),• Discuss current economic and logistic barriers to appropriate HF therapy in the managed care setting,• Apply methods to enable optimal cost management of newer heart failure therapy to be realized by multiple heart failure stakeholders including managed care organizations